You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Demographic characteristics of study subjects

From: Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

  Piperacillin/tazobactam (N = 33) Cefepime (N = 6) Ertapenem (N = 33) p-value
Age 68.8 ± 14.4 75.3 ± 6.6 65.2 ± 16.9 0.281
Female 30 (90.9) 3 (50.0) 26 (78.8) 0.049
Comorbidity, n (%)
 Ischemic heart disease 0 (0) 0 (0) 1 (3.0) 1.000
 Diabetes mellitus 12 (36.4) 1 (16.7) 15 (45.5) 0.474
 Cerebrovascular accident 5 (15.2) 1 (16.7) 2 (6.1) 0.420
 Dementia 3 (9.1) 0 (0) 2 (6.1) 1.000
 Hemiplegia 2 (6.1) 0 (0) 2 (6.1) 1.000
 Congestive heart failure 5 (15.2) 1 (16.7) 1 (3.0) 0.230
 COPD 1 (3.0) 0 (0) 1 (3.0) 1.000
 Chronic kidney disease 2 (6.1) 0 (0) 2 (6.1) 1.000
 Liver cirrhosis 2 (6.1) 0 (0) 4 (12.1) 0.809
 Solid tumor 6 (18.2) 1 (16.7) 7 (21.2) 1.000
 Lymphoma 1 (3.0) 0 (0) 2 (6.1) 1.000
 None 12 (36.4) 2 (33.3) 12 (36.4) 1.000
Charlson comorbidity index 4.7 ± 3.0 4.7 ± 1.0 4.5 ± 3.0 0.951
Bacteremia, n (%) 9 (27.3) 0 (0) 7 (21.2) 0.477
Septic shock, n (%) 9 (24.2) 2 (33.3) 11 (33.3) 0.928
APACH II score 12.9 ± 2.9 16.5 ± 6.4 16.6 ± 5.6 0.298